ReviewClinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology2014
Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine.
Review in Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- NodoMap: A single-cell and spatial transcriptomic atlas of the mouse nodose ganglion.Cell press blue · 2026Article
- Treatment-resistant depression: molecular mechanisms and management.Molecular biomedicine · 2024Review
- Major depressive disorder: Validated treatments and future challenges.World journal of clinical cases · 2021Review
- Neurobiological basis of chiropractic manipulative treatment of the spine in the care of major depression.Acta bio-medica : Atenei Parmensis · 2020Review
- LMDS-1, a potential TrkB receptor agonist provides a safe and neurotrophic effect for early-phase Alzheimer's disease.Psychopharmacology · 2020Article
- Vagus nerve stimulation as adjunctive therapy in patients with difficult-to-treat depression (RESTORE-LIFE): study protocol design and rationale of a real-world post-market study.BMC psychiatry · 2020Article
- Cardiac dysautonomia in depression - heart rate variability biofeedback as a potential add-on therapy.Neuropsychiatric disease and treatment · 2019Review
- Low Vs. High Alcohol: Central Benefits Vs. Detriments.Neurotoxicity research · 2018Review
- Review of the neurological benefits of phytocannabinoids.Surgical neurology international · 2018Review
- Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.Current psychiatry reports · 2017Review
- Vagal Nerve Stimulation for Treatment-Resistant Depression.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- New targets for rapid antidepressant action.Progress in neurobiology · 2017Review
- Role of the vagus nerve in the development and treatment of diet-induced obesity.The Journal of physiology · 2016Review
- Duality of Antidepressants and Neuroprotectants.Neurotoxicity research · 2016Review
- Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2016Article
- Role of TrkB in the anxiolytic-like and antidepressant-like effects of vagal nerve stimulation: Comparison with desipramine.Neuroscience · 2016Article
- The role of the gut-brain axis in alcohol use disorders.Progress in neuro-psychopharmacology & biological psychiatry · 2016Review
- Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-resistant Major Depression.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2015Article
- Ketamine, Transcranial Magnetic Stimulation, and Depression Specific Yoga and Mindfulness Based Cognitive Therapy in Management of Treatment Resistant Depression: Review and Some Data on Efficacy.Depression research and treatment · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment resistant depression (TRD) is a global health concern affecting a large proportion of depressed patients who then require novel therapeutic options. One such treatment option that has received some attention in the past several years is vagal nerve stimulation (VNS). The present review briefly describes the relevance of this treatment in the light of other existing pharmacological and non-pharmacological options. It then summarizes clinical findings with respect to the efficacy of VNS. The anatomical rationale for its efficacy and other potential mechanisms of its antidepressant effects as compared to those employed by classical antidepressant drugs are discussed. VNS has been approved in some countries and has been used for patients with TRD for quite some time. A newer, fast-acting, non-invasive pharmacological option called ketamine is currently in the limelight with reference to TRD. This drug is currently in the investigational phase but shows promise. The clinical and preclinical findings related to ketamine have also been summarized and compared with those for VNS. The role of neurotrophin factors, specifically brain derived neurotrophic factor and its receptor, in the beneficial effects of both VNS and ketamine have been highlighted. It can be concluded that both these therapeutic modalities, while effective, need further research that can reveal specific targets for intervention by novel drugs and address concerns related to side-effects, especially those seen with ketamine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.